Printer Friendly

Spectranetics Launches Next Generation Lead Locking Device.

COLORADO SPRINGS, Colo., May 12 /PRNewswire-FirstCall/ -- Spectranetics Corporation announced today that it has recently received 510(k) clearance from the Food and Drug Administration (FDA) to market its enhanced lead locking device (LLD(R) E) featuring several design enhancements that will save deployment time, improve navigation through tortuous vascular anatomy and provide additional stability to the pacemaker or defibrillator lead being removed. The market launch for this device began last week at the Heart Rhythm Society meeting in New Orleans, Louisiana.

Charles Kennergren, M.D., PhD, a cardiovascular surgeon at Sahlgrenska University Hospital in Goteborg, Sweden, stated, "Tortuous leads are one of the major challenges in lead extraction. The improved tip flexibility of the new Spectranetics LLD E can significantly enhance trackability in these often demanding cases."

The LLD E may be used alone or in combination with the Spectranetics Laser Sheath. Together, these devices are marketed as CLeaRS(R) (Cardiac Lead Removal System). The LLD E utilizes proprietary technology that locks onto the entire working length of the inner wall of the lead being removed, providing a stable platform for the lead extraction.

About Spectranetics

Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Our CVX-300(R) excimer laser is the only system approved by the FDA for multiple cardiovascular procedures, including coronary atherectomy, and the removal of problematic pacemaker and defibrillator leads. Nearly all of our FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. In April 2004, we obtained 510(k) clearance from the FDA for the laser-based treatment of patients suffering from total occlusions (blockages) in their leg arteries that are not crossable with a guide wire.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

Spectranetics and CVX-300 are registered trademarks of The Spectranetics Corporation.
 COMPANY CONTACT:
 Spectranetics Corporation
 John Schulte, Chief Executive Officer
 Guy Childs, Chief Financial Officer
 (719) 633-8333
 http://www.spectranetics.com/

 INVESTOR & MEDIA CONTACTS:
 Lippert/Heilshorn & Associates, Inc.
 Bruce Voss
 Ina McGuinness
 (310) 691-7100
 http://www.lhai.com/



CONTACT: John Schulte, Chief Executive Officer, or Guy Childs, Chief Financial Officer, both of Spectranetics Corporation, +1-719-633-8333; or Investors & Media, Bruce Voss, or Ina McGuinness, both of Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, for Spectranetics Corporation

Web site: http://www.lhai.com/

Web site: http://www.spectranetics.com/
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:May 12, 2005
Words:615
Previous Article:A/S Steamship Co TORM Announces Profit for First Quarter 2005 of USD 54.9 Million (DKK 311.8 Million) Before Tax and Profits From Sale of Vessels.
Next Article:Recommendation from the Board of Directors of Riddarhyttan Resources.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters